US-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has announced the appointment of Sean (Xi-Yong) Fu, PhD, MBA, as its permanent Chief Executive Officer (CEO), effective November 1, 2024. Dr. Fu, who has been serving as Interim CEO since July 15, 2024, will also continue his role as a member of the Board of Directors of I-Mab.
Dr. Fu’s Extensive Experience in the Life Sciences Industry
Dr. Fu brings over 20 years of industry experience in the life sciences sector, with a track record in leading and developing clinical-stage assets. He most recently served as the Operating Partner of ABio-X, a life sciences incubation platform. Prior to ABio-X, Dr. Fu was the co-founder and CEO of RVAC Medicines (RVAC), an mRNA platform company. Before founding RVAC, he held the position of Group VP and head of International R&D for Luye Pharma Group, with oversight over organizations in Boston, Princeton, Germany, Switzerland, and Japan. Dr. Fu also served as CEO of GeneLeap, a Luye subsidiary focusing on DNA and RNA therapeutics. He previously spent 15 years at Merck & Co. (Merck), where his responsibilities included R&D, business development, finance, and operational management. Notably, he managed the finances for the late-stage clinical portfolio and led the integration of the global R&D network following Merck’s landmark USD42 billion merger with Schering-Plough Corporation. Dr. Fu holds a PhD in materials science and engineering from the Ohio State University and an MBA from the Wharton School of the University of Pennsylvania.- Flcube.com
